Demyelinating neuropathy with anti‐CRMP5 antibodies predating diagnosis of breast carcinoma: Favorable outcome after cancer therapy

Samarasekera, Shanika; Rajabally, Yusuf A.

doi:10.1002/mus.22036

Cited by 16 publications

(8 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We identified 6 published cases of CIDP associated with breast cancer. 24,37,[49][50][51] In all of 5 cases with documented history, the neuropathy preceded the cancer diagnosis by months to years. Sensory ataxia predominated in 2 cases, and cranial nerve involvement was reported in 1.…”

Section: Chronic Inflammatory Neuropathies Associated Withmentioning

confidence: 99%

Chronic inflammatory demyelinating polyneuropathy and malignancy: A systematic review

Rajabally

Attarian

2017

Muscle and Nerve

Self Cite

View full text Add to dashboard Cite

A systematic review of the literature was performed on the association of chronic inflammatory demyelinating polyneuropathy (CIDP) with malignancy. Hematological disorders are the most common association, particulalry non-Hodgkin lymphoma. CIDP frequently precedes the malignancy diagnosis, and there is a favorable CIDP response to treatment more than 70% of the time. Melanoma is the second most common association and may be accompanied by antiganglioside antibodies; CIDP shows a good response to immunotherapy. Other cancers are rare, with variable timings and presentations but good responses to immunomodulation and/or cancer therapy. Unusual neurological features such as ataxia, distal/upper limb predominance, or cranial/respiratory/autonomic involvement may suggest associated malignancy as may abdominal pain, diarrhea/constipation, poor appetite/weight loss, dermatological lesions, and lymphadenopathy. In the appropriate clinical and electrophysiological setting, CIDP associated with cancer should be considered. Immunomodulatory therapy, cancer treatment alone, or a combination may be effective. Muscle Nerve 57: 875-883, 2018.

show abstract

Section: Chronic Inflammatory Neuropathies Associated Withmentioning

confidence: 99%

Chronic inflammatory demyelinating polyneuropathy and malignancy: A systematic review

Rajabally

Attarian

2017

Muscle and Nerve

Self Cite

View full text Add to dashboard Cite

show abstract

“…Other antibodies are also associated with paraneoplastic neuropathy. In one example, a patient developed a sensory-predominant, mildly ataxic demyelinating neuropathy 2 years preceding eventual diagnosis of breast cancer [27]. She also showed elevated cerebrospinal fluid protein and a serum IgG kappa paraprotein.…”

Section: Paraneoplastic Antibodiesmentioning

confidence: 98%

Advances in the Laboratory Evaluation of Peripheral Neuropathies

Huan

Bromberg

2011

Curr Neurol Neurosci Rep

View full text Add to dashboard Cite

Peripheral neuropathy is a common clinical problem in neurology and laboratory testing is an integral part of diagnosis. In the past few years, practice parameters have been published to establish an evidence-based guide to neuropathy testing. There are many tests that are common and accepted in practice, but there is no clear mandate on which tests are necessary. This article reviews recent practice parameter publications as well as other updates in laboratory testing for peripheral neuropathy, including the roles of lipid profile, genetic testing, antibody titers, and B(12) testing in a specific dopamine-treated Parkinson's patients. These can serve as recommendations to help guide laboratory testing.

show abstract

“…Other antibodies, however, have been and continue to be identified and associated with PN, including anti-Yo, anti-Ri, and antiamphiphysin. 34,[37][38][39] In addition to small cell lung cancer, other associated malignancies include adenocarcinomas, lymphomas, thymomas, breast cancer, and gastrointestinal cancers. As new antibody and oncologic associations continue to be discovered, it is paramount to screen broadly for various paraneoplastic antibodies and to retain a high index of suspicion for paraneoplastic disease and occult malignancy in patients with unexplained PN.…”

Section: Antibody-associated Paraneoplastic Neuropathiesmentioning

confidence: 99%

Neuropathy of Connective Tissue Diseases and Other Systemic Diseases

Jin

Shin

2019

Semin Neurol

View full text Add to dashboard Cite

Peripheral neuropathy is associated with numerous systemic diseases. It is often the heralding finding, which can lead to earlier diagnoses and better outcomes. An understanding of the epidemiology and clinical features of these diseases is paramount to their diagnosis and management. This article will focus on neuropathy associated with connective tissue diseases, monoclonal gammopathies, paraneoplastic disorders, medications including chemotherapeutic agents, nutritional deficiencies, alcohol, and toxins.

show abstract

Demyelinating neuropathy with anti‐CRMP5 antibodies predating diagnosis of breast carcinoma: Favorable outcome after cancer therapy

Abstract: This case widens the range of paraneoplastic manifestations of breast carcinoma to include anti-CRMP5 antibody-positive sensory ataxic demyelinating neuropathy, which, in this patient, improved after cancer treatment.

Cited by 16 publications

References 11 publications

Chronic inflammatory demyelinating polyneuropathy and malignancy: A systematic review

Chronic inflammatory demyelinating polyneuropathy and malignancy: A systematic review

Advances in the Laboratory Evaluation of Peripheral Neuropathies

Neuropathy of Connective Tissue Diseases and Other Systemic Diseases

Contact Info

Product

Resources

About